Recombinant DNA Technology Market: Global Industry Analysis and Forecast (2021-2027) by Technology, Product, Application, Specimen, and Region

Recombinant DNA Technology Market size was valued at US$ 27.01 Bn in 2020 and the Medical segment dominated the growth of the Recombinant DNA Technology Market.

Recombinant DNA Technology Market Overview:

Recombinant DNA (rDNA) is a technique for cutting and pasting DNA sequences of interest using enzymes. The recombined DNA sequences can be inserted into vectors, which transport the DNA to a suitable host cell where it can be replicated or expressed. Recombinant DNA technology has been successfully employed to create human proteins in microbes, such as insulin and growth hormone, which are used in illness therapy. Recombinant DNA Technology Market To know about the Research Methodology :- Request Free Sample Report The report has covered the market trends from 2015 to forecast the market through 2026. 2020 is considered a base year however 2020's numbers are on the real output of the companies in the market. Special attention is given to 2020 and the effect of lockdown on the demand and supply, and also the impact of lockdown for the next two years on the market. Some companies have done well in lockdown also and specific strategic analysis of those companies is done in the report.

Recombinant DNA Technology Market Dynamics:

Scientists now have extraordinary control over genetic material thanks to recombinant DNA (rDNA) technology. This has allowed it to be used in a wide range of applications, both conventional and non-traditional. In recent years, considerable progress has been made in the manufacturing of recombinant medications and therapies without the use of human donors. The commercial success of genetically modified insulin for diabetes therapy is a typical example of this feat. The potential of rDNA approaches in different aspects of illness treatment is being investigated by biotech and pharmaceutical companies. Furthermore, by permitting the synthesis of a recombinant DNA molecule, the progressive evolution of rDNA techniques has drafted new possibilities in biopharmaceutical development. The presence of a strong biopharmaceutical pipeline, particularly one for recombinant proteins, is likely to accelerate the adoption of this technology. The expansion of this field is partly due to the development of recombinant products using rDNA techniques in combination with CRISPR/Cas9 nuclease, ZFN, and TALEN allowing easy and precise genomic editing without being limited by organisms. The effectiveness of rDNA technology has been demonstrated by dozens of review studies conducted by researchers management. The expansion of genetically modified (GM) crop acreage around the world demonstrates the technology's success in the agriculture and food sectors. This has prompted it to be used in non-traditional applications such as the creation of biofuels and biopesticides to combat environmental challenges. However, because of the associated ethical problems in many applications like gene therapy, the use of this technology has been a source of controversy. Scientific and ethical considerations differ by discipline in the different domains of medicine, agriculture, and the environment.

Recombinant DNA Technology Market Segment Analysis:

The Medical segment is anticipated to adhere to the growth of the Recombinant DNA Technology Market. The medical profession has been transformed by rDNA technology, which is having an ever-increasing impact on clinical practice. It has aided illness treatment by allowing for the replacement of damaged and sick genes with new ones. Therapeutic drugs, recombinant proteins, and vaccines are divided further into the medical section. Therapeutic agents, in particular, have surpassed their counterpart categories due to the presence of a large number of genetically altered products for clinical use. Due to the development of a healthy vaccine pipeline, vaccines are projected to be a source of attractive income generation in the approaching years. Growth in this market is expected to be fueled by advances in genetic engineering and process development. The success of GM crops is driving the non-medical component of this business. The expression system segment is estimated to grab larger market attention in the Recombinant DNA Technology Market. This technology's two most important components are the expression system and the cloning vector. Since ongoing improvements for effective protein expression and its further isolation on a wide scale, expression systems accounted for the highest share. Mammalian, bacterial, insect, and yeast expression systems are the most commonly employed. The emergence of cell lines like HEK293 and Chinese Hamster Ovarian (CHO) has helped mammalian expression systems gain a considerable part of the market. In the coming years, continuous research investigations to explore the potential of plants as expression systems are likely to drive the use of plant expression systems for GM product development. Cloning vectors are well-acknowledged as the foundation for producing DNA inserts. Cohen received the "2016 Biotechnology Heritage Award" in 2016 for his work on rDNA plasmids. Such accomplishments are projected to have a beneficial impact on the segment's growth throughout the projection period. Recombinant DNA Technology Market The health and diseases segment is supplementing the growth of the Recombinant DNA Technology Market. Major developments in genetic engineering have revolutionized how these technologies are used in health and disease, agriculture, and the environment. The health and diseases application has taken the lead and is likely to continue to do so during the predicted period. The prevalence of a wide spectrum of recombinant products for human illness treatment, such as medicines, vaccines, and enzyme replacements, can be attributable to this substantial percentage. Furthermore, the increased usage of this technology for the treatment of animal diseases has aided this segment's growth. With the increasing burden of crop improvement and the resulting stress on farmers to fulfill customer demand, this technology has steadily grown as a panacea for tackling these agricultural difficulties. As a result, recombination approaches have seen significant success in food and agriculture applications. In the future years, other applications, such as biofuel production, are projected to increase significantly. This is primarily due to continuous scientific efforts to expand the space's capabilities.

Recombinant DNA Technology Market Regional Insights:

North America is dominating the growth of the regional market in the forecast period. The fact that a big number of biopharmaceutical manufacturing participants are headquartered in the United States accounts for the largest proportion of the North American region. Furthermore, the availability of strong regulatory agencies to oversee numerous ethical and scientific concerns related to the use of technology has fueled regional development. In July 2017, this country had the first FDA approval of a gene therapy medicine in the United States. The treatment for leukaemia was developed as a consequence of a cooperation between the University of Pennsylvania and Novartis Corporation. As a result, the region's usage of rDNA technology is projected to increase. The objective of the report is to present a comprehensive analysis of the Recombinant DNA Technology Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Recombinant DNA Technology Market dynamics, structure by analyzing the market segments and projecting the Recombinant DNA Technology Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the Recombinant DNA Technology Market make the report investor’s guide.

Recombinant DNA Technology Market Scope: Inquire before buying

Recombinant DNA Technology Market

Recombinant DNA Technology Market, by Region

• North America o US o Canada o Mexico • Europe o U.K o France o Germany o Italy o Spain o Sweden o CIS Countries o Rest of Europe • Asia Pacific o China o India o Japan o South Korea o Australia o ASEAN o Rest of Asia Pacific • The Middle East and Africa o South Africa o GCC Countries o Egypt o Nigeria o Rest of ME&A • South America o Brazil o Argentina o Rest of South America

Recombinant DNA Technology Market Key Players

F. Hoffmann-La Roche Ltd (Genentech, Inc) • Profacgen • Amgen Inc • Novartis AG • GenScript • Pfizer Inc • Novo Nordisk A/S • Eli Lilly and Company • Sanofi • Merck & Co., Inc. • Biogen • Biocon • GlaxoSmithKline plc • New England Biolabs. • Cibus • Monsanto Company • Horizon Discovery Group PLC. FAQs: 1. What is the Recombinant DNA Technology market value in 2020? Ans: The Recombinant DNA Technology market value in 2020 was estimated as 27.01 Billion USD. 2. Which Product Type is likely to dominate the Recombinant DNA Technology market growth? Ans: Medical segment dominated the growth of Recombinant DNA Technology and accounted for the highest market share of 47.2% in 2019. 3. Which Region is expected to dominate the Recombinant DNA Technology market during the forecast period? Ans: In 2020, North America dominated the Recombinant DNA Technology market and accounted for the largest revenue share of 59.4%. 4. What are the factors driving the Recombinant DNA Technology market? Ans: Key factors that are driving the Recombinant DNA Technology market growth include gradual evolution of rDNA techniques, Gene Modification, and investment in Biotechnology. 5. Who are the key players in the Recombinant DNA Technology market? Ans: Some key players operating in the F. Hoffmann-La Roche Ltd (Genentech, Inc); Profacgen; Amgen Inc; Novartis AG; GenScript; Pfizer Inc; Novo Nordisk A/S; Eli Lilly and Company; Sanofi; Merck & Co., Inc.; Biogen; Biocon; GlaxoSmithKline plc; New England Biolabs.; Cibus; Monsanto Company, and Horizon Discovery Group PLC.
1. Global Recombinant DNA Technology Market: Research Methodology 2. Global Recombinant DNA Technology Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Recombinant DNA Technology Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Recombinant DNA Technology Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Recombinant DNA Technology Market Segmentation 4.1 Global Recombinant DNA Technology Market, by Product (2020-2027) • Medical o Therapeutic Agent o Human Protein o Vaccine • Non-medical o Biotech Crops o Specialty Chemicals o Others 5.2 Global Recombinant DNA Technology Market, by Component (2020-2027) • Expression System o Mammalian o Bacteria o Yeast o Baculovirus / insect o Others • Cloning Vector 5.3 Global Recombinant DNA Technology Market, by Application (2020-2027) • Food & Agriculture • Health & Disease o Human o Animal • Environment • Others 5.4 Global Recombinant DNA Technology Market, by End-user (2020-2027) • Biotechnology and Pharmaceutical Companies • Academic & Government Research Institutes Others 5. North America Recombinant DNA Technology Market (2020-2027) 5.1 North America Recombinant DNA Technology Market, by Product (2020-2027) • Medical o Therapeutic Agent o Human Protein o Vaccine • Non-medical o Biotech Crops o Specialty Chemicals o Others 5.2 North America Recombinant DNA Technology Market, by Component (2020-2027) • Expression System o Mammalian o Bacteria o Yeast o Baculovirus / insect o Others • Cloning Vector 5.3 North America Recombinant DNA Technology Market, by Application (2020-2027) • Food & Agriculture • Health & Disease o Human o Animal • Environment • Others 5.4 North America Recombinant DNA Technology Market, by End-user (2020-2027) • Biotechnology and Pharmaceutical Companies • Academic & Government Research Institutes • Others 6. Asia Pacific Recombinant DNA Technology Market (2020-2027) 6.1. Asia Pacific Recombinant DNA Technology Market, by Product (2020-2027) 6.2. Asia Pacific Recombinant DNA Technology Market, by Component (2020-2027) 6.3. Asia Pacific Recombinant DNA Technology Market, by Application (2020-2027) 6.4. Asia Pacific Recombinant DNA Technology Market, by End-user (2020-2027) 6.5. Asia Pacific Recombinant DNA Technology Market, by Country (2020-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Recombinant DNA Technology Market (2020-2027) 7. 1 Middle East and Africa Recombinant DNA Technology Market, by Product (2020-2027) 7.2. Middle East and Africa Recombinant DNA Technology Market, by Component (2020-2027) 7.3. Middle East and Africa Recombinant DNA Technology Market, by Application (2020-2027) 7.4. Middle East and Africa Recombinant DNA Technology Market, by End-user (2020-2027) 7.5. Middle East and Africa Recombinant DNA Technology Market, by Country (2020-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Recombinant DNA Technology Market (2020-2027) 8.1. Latin America Recombinant DNA Technology Market, by Product (2020-2027) 8.2. Latin America Recombinant DNA Technology Market, by Component (2020-2027) 8.3. Latin America Recombinant DNA Technology Market, by Application (2020-2027) 8.4. Latin America Recombinant DNA Technology Market, by End-user (2020-2027) 8.5. Latin America Recombinant DNA Technology Market, by Country (2020-2027) • Brazil • Argentina • Rest Of Latin America 9. European Recombinant DNA Technology Market (2020-2027) 9.1. European Recombinant DNA Technology Market, by Product (2020-2027) 9.2. European Recombinant DNA Technology Market, by Component (2020-2027) 27.01. European Recombinant DNA Technology Market, by Application (2020-2027) 9.4. European Recombinant DNA Technology Market, by End-user (2020-2027) 9.5. European Recombinant DNA Technology Market, by Country (2020-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1.1. Stemcell 10.1.1.1. Company Overview 10.1.1.2. Financial Overview 10.1.1.3. Geographic Footprint 10.1.1.4. Grade Portfolio 10.1.1.5. Business Strategy 10.1.1.6. Recent Developments 10.1.2. F. Hoffmann-La Roche Ltd (Genentech, Inc) 10.1.3. Profacgen 10.1.4. Amgen Inc 10.1.5. Novartis AG 10.1.6. GenScript 10.1.7. Pfizer Inc 10.1.8. Novo Nordisk A/S 10.1.9. Eli Lilly and Company 10.1.10. Sanofi 10.1.11. Merck & Co., Inc. 10.1.12. Biogen 10.1.13. Biocon 10.1.14. GlaxoSmithKline plc 10.1.15. New England Biolabs. 10.1.16. Cibus 10.1.17. Monsanto Company 10.1.18. Horizon Discovery Group PLC.

About This Report

Report ID 125919
Category Healthcare
Published Date Nov 2021
Updated Date
Contact Us